Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients.

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

Update, March 1, 5 PM: Ramsay Baghadi of the RPM Report says that the Cardiorenal committee will take up the apixaban NDA on Mary 22 and the rivaroxaban supplemental NDA for the ACS indication on ...

Gastrointestinal (GI) bleeds are about 20%–28% less likely in patients with atrial fibrillation (AF) taking apixaban (Eliquis) compared with other direct oral anticoagulants (DOACs), an ...

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P ...

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...